



NOTRE DAME INTERMÉDICA PARTICIPAÇÕES S.A.

Corporate ID No 19.853.511/0001-84

Listed on the B3 Stock Exchange

MATERIAL FACT

Notre Dame Intermédica Participações S.A. (“**Company**” or “**GNDI**”), pursuant to the provisions of article 157, paragraph 4, of Law No. 6,404/76 of CVM Rule No. 358/02, hereby announces to its shareholders and to the Market in general that, on October 23, 2020, Clinipam – Clínica Paranaense de Assistência Médica Ltda. (“**Clinipam**”), subsidiary of the company, entered into a purchase and sale agreement to acquire Hospital e Maternidade Santa Brígida S.A. (“**Hospital Santa Brígida**”) (“**Transaction**”).

With the completion of the Transaction, the Company will hold, indirectly 97% (ninety-seven percent) of the quotas of Hospital Santa Brígida. The Enterprise Value was paid in cash, deducted the indebtedness and a portion retained for contingencies.

Located in Curitiba (PR), Hospital Santa Brígida operates a Maternal and Child Hospital with 72 beds, 15 of which are ICUs, 4 obstetric rooms and 5 emergency room offices, in addition to a diagnostic area with ultrasonography, endoscopy, radiography and clinical analysis laboratory.

In 2019, Hospital Santa Brígida presented a consolidated net revenue of R\$ 31.2 million. The Enterprise Value was R\$ 48.5 million, including the real estate with approximately 6,000 m² of built-up area, equivalent to approximately R\$ 700,000 per hospital bed. The integration plan contemplates operational and administrative synergies with Clinipam operations in the metropolitan area of Curitiba, which already owns two general hospitals, one imaging diagnosis center, eleven clinical centers, three emergency rooms and a preventive care unit.

The closing of the Transaction is not subject to the approval by the Brazilian Agency of Supplemental Health (Agência Nacional de Saúde Suplementar - ANS) and the Brazilian Antitrust Council (Conselho Administrativo de Defesa Econômica – CADE).

With the Transaction, the Company demonstrates the intention to maintain its growth strategy in the south region of the country with continuous investments in the expansion and strengthening of its owned network, reinforcing its commitment to create value for its shareholders, customers and society.

The Company clarifies that the Transaction is not subject to and, therefore, will not be submitted to shareholders’ approval provided for in Article 256 of Law No. 6,404/76, nor will entail, pursuant to the guidance provided in the Official Letter/CVM/SEP/No. 02/2018, the withdrawal right to the Company’s shareholders, considering that the acquisition was performed by Clinipam, which is a privately held company and subsidiary of the Company.

São Paulo, October 26, 2020.

Glauco Desiderio
Investor Relations Officer